Skip to content

Inspection Record

Amorepacific Canada Inc — Health Canada Inspection Findings

Health CanadaInspected 2026-07-28 7 findingsDeviation, CAPA, and investigationOther quality systemQuality unit oversightLaboratory and QC controlsEquipment and facilityStability and storage

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

2Other quality system

The master production documents were inadequate.

3Quality unit oversight

The quality control department did not evaluate the results of the annual product quality review.

4Laboratory and QC controls

The examination and/or approval of fabrication, packaging, labelling, testing, storage, and/or the transportation method and procedures by the person in charge of the quality control department before implementation was inadequate.

5Equipment and facility

The training of personnel in good manufacturing practices and/or the maintenance of records was inadequate.

6Stability and storage

The evidence used to demonstrate the transportation and/or storage conditions of each lot or batch of the drug was inadequate.

7Other quality system

Deficiencies were noted with the procedure for the assessment of returned drugs being considered for resale.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the Health Canada inspection on 2026-07-28. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Amorepacific Canada Inc findings history — including this company's other documentsAll Health Canada findings Health Canada documents, 2026 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.